Bioventus Inc. (NASDAQ:BVS) Given Average Rating of "Buy" by Brokerages

Key Points

• Analysts give Bioventus a consensus "Buy" rating (1 hold, 3 buy, 1 strong buy) with an average 12‑month target of $14.00, and several firms recently raised targets (e.g., Craig Hallum to $16, Cantor Fitzgerald to strong‑buy).
• Bioventus reported Q results beating estimates with $0.24 EPS vs. $0.22 expected and $157.9M revenue, and set FY2026 guidance of $0.730–$0.770 EPS (consensus ~0.76 EPS).
• The stock opened at $9.87 with a market cap of ~$820.7M and a P/E of ~29.9, while insiders own 33% (one director sold 12,000 shares) and institutional investors hold about 62.9% of shares.

Shares of Bioventus Inc. (NASDAQ:BVS - Get Free Report) have been given a consensus recommendation of "Buy" by the five analysts that are currently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $14.00.

BVS has been the subject of several analyst reports. Craig Hallum lifted their price objective on shares of Bioventus from $15.00 to $16.00 and gave the stock a "buy" rating in a research note on Friday, March 6th. Cantor Fitzgerald upgraded shares of Bioventus to a "strong-buy" rating in a research report on Wednesday, March 4th. CJS Securities initiated coverage on shares of Bioventus in a report on Friday, March 27th. They set a "market outperform" rating and a $14.00 target price on the stock. Finally, Barrington Research lifted their price target on shares of Bioventus from $13.00 to $14.00 and gave the company an "outperform" rating in a research report on Friday, March 6th.

Bioventus Stock Performance

Shares of NASDAQ BVS opened at $9.87 on Friday. The company has a debt-to-equity ratio of 1.22, a current ratio of 1.70 and a quick ratio of 1.19. The firm has a market cap of $820.69 million, a price-to-earnings ratio of 29.91 and a beta of 0.70. The stock's fifty day moving average price is $9.19 and its two-hundred day moving average price is $8.12. Bioventus has a one year low of $5.81 and a one year high of $10.76.

Bioventus (NASDAQ:BVS - Get Free Report) last posted its earnings results on Thursday, March 5th. The company reported $0.24 earnings per share for the quarter, topping analysts' consensus estimates of $0.22 by $0.02. Bioventus had a return on equity of 28.88% and a net margin of 4.00%.The company had revenue of $157.90 million during the quarter. Bioventus has set its FY 2026 guidance at 0.730-0.770 EPS. On average, equities analysts forecast that Bioventus will post 0.76 EPS for the current year.

Insiders Place Their Bets

In other Bioventus news, Director Michelle Mcmurry-Heath sold 12,000 shares of Bioventus stock in a transaction on Wednesday, March 11th. The stock was sold at an average price of $8.79, for a total value of $105,480.00. Following the completion of the transaction, the director directly owned 44,997 shares of the company's stock, valued at $395,523.63. The trade was a 21.05% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 33.00% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of BVS. Nantahala Capital Management LLC boosted its stake in shares of Bioventus by 4.1% in the 4th quarter. Nantahala Capital Management LLC now owns 6,047,403 shares of the company's stock valued at $44,993,000 after purchasing an additional 236,741 shares in the last quarter. Vanguard Group Inc. increased its position in Bioventus by 4.4% during the 3rd quarter. Vanguard Group Inc. now owns 2,924,788 shares of the company's stock worth $19,567,000 after purchasing an additional 122,749 shares in the last quarter. Royce & Associates LP lifted its stake in Bioventus by 15.6% in the 3rd quarter. Royce & Associates LP now owns 1,262,976 shares of the company's stock valued at $8,449,000 after purchasing an additional 170,900 shares during the last quarter. Geode Capital Management LLC boosted its position in Bioventus by 1.8% in the fourth quarter. Geode Capital Management LLC now owns 1,120,238 shares of the company's stock valued at $8,337,000 after buying an additional 19,388 shares in the last quarter. Finally, State Street Corp boosted its position in Bioventus by 1.7% in the fourth quarter. State Street Corp now owns 891,024 shares of the company's stock valued at $6,629,000 after buying an additional 14,590 shares in the last quarter. Institutional investors and hedge funds own 62.94% of the company's stock.

Bioventus Company Profile

Bioventus, headquartered in Durham, North Carolina, is a global medical device company specializing in orthobiologic solutions aimed at accelerating healing and improving patient outcomes in musculoskeletal conditions. The company develops and commercializes a portfolio of non‐surgical therapies designed to address bone healing, osteoarthritis pain management and soft tissue repair. Its flagship EXOGEN® Ultrasound Bone Healing System utilizes low‐intensity pulsed ultrasound technology to stimulate bone growth and has been widely used in the management of delayed fractures and nonunions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.